CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Nondigestible oligosaccharide (NDO)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00022867
NCT00022867Phase 2Completed
CompareCT.gov

Optimization of Calcium Absorption and Bone Formation During Early Puberty

Baylor College of Medicine·interventional·Posted Aug 16, 2001·Updated Jul 24, 2015

In Brief

A Phase 2 clinical trial evaluating Nondigestible oligosaccharide (NDO) for Osteoporosis and Osteopenia. Completed, across 1 site.

Detailed Summary

Increasing bone mass during puberty can ultimately decrease the risk of developing osteoporosis, which causes bones to weaken and break more easily later in life. The purpose of this study is to compare calcium absorption and bone growth in boys and girls on diets including either a nondigestible oligosaccharide (NDO) or simple sugar.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Osteopenia
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 16, 2001
Enrollment StartMay 1, 2001
Primary CompletionJan 1, 2005
Study CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 24.9 years ago

Interventions

Nondigestible oligosaccharide (NDO)drug